Close Menu

Natera

A brief recap of the news for Jan 11, 2019: Danaher, Natera, Chembio, and More

The company plans to focus on increasing its NIPT reimbursement as well as on pharmaceutical deals for its oncology test and launching a kidney transplantation test.

Novacyt said this week that its revenue from continuing operations for full-year 2018 will be in the range of €13.7 million to €14.4 million ($17.4 million to $18.3 million), following its decision in December to sell its Novaprep cytology business and clinical laboratory operations.

At the conference, researchers presented data from a number of studies using molecular diagnostic tools to better characterize breast cancer recurrence and treatment outcomes.

November's modest gain followed a tough October, when the index down almost 9 percent. Meridian Bio paced the gainers, and NantHealth was the steepest decliner.

Natera plans to launch its clinical oncology and transplantation tests next year and is hopeful that guidelines endorsing NIPT for average-risk pregnancies are imminent.

The molecular diagnostics firm grew year-over-year testing volumes by 28 percent to 167,172.

The investment bank said it is encouraged by the company's strong pipeline and position among its competitors but sees further upside for its stock.

The pharma company plans to use the Signatera assay to determine whether it can identify patients who will respond to immunotherapy.

CareDx and Invitae each had massive share-price gains last month. Exact Sciences, GenMark, and Natera also saw sizeable increases in their stock prices.

Pages